Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2021

Open Access 01-12-2021 | Kaposi Sarcoma | Letter to the Editor

Authors’ response to “Evaluation of Treatments for HIV-Associated Kaposi Sarcoma in Africa”

Authors: Matthew E. Coldiron, Ana Gabriela Gutierrez Zamudio, Rolanda Manuel, Iza Ciglenecki, Laurence Toutous Trellu, Lucas Molfino

Published in: Infectious Agents and Cancer | Issue 1/2021

Login to get access

Excerpt

We thank Drs Krown and Borok for the interest they have shown in our work and the opportunity they give us to draw attention to the extremely poor access to cancer treatment in resource-limited settings. Nonetheless, we feel it is important to clarify certain points. …
Literature
1.
Coldiron ME, Gutierrez Zamudio AG, Manuel R, Luciano G, Rusch B, Ciglenecki I, et al. Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin. Infect Agent Cancer. 2021;16:2
2.
Krown SE, Moser CB, Macphail P, Matining RM, Godfrey C, Caruso SR, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020;395:1195–207.CrossRef
3.
Fardhdiani V, Molfino L, Zamudio AG, Manuel R, Luciano G, Ciglenecki I, et al. HIV-associated Kaposi’s sarcoma in Maputo, Mozambique: Outcomes in a specialized treatment center, 2010–2015. Infect Agent Cancer. 2018;13:5.
Metadata
Title
Authors’ response to “Evaluation of Treatments for HIV-Associated Kaposi Sarcoma in Africa”
Authors
Matthew E. Coldiron
Ana Gabriela Gutierrez Zamudio
Rolanda Manuel
Iza Ciglenecki
Laurence Toutous Trellu
Lucas Molfino
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2021
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-021-00372-5

Other articles of this Issue 1/2021

Infectious Agents and Cancer 1/2021 Go to the issue

Research Article

Healthcare resource utilization and costs associated with anogenital warts in Morocco

Research Article

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin

Research Article

Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women

Review

Managing head and neck cancer patients during the COVID-19 pandemic: the experience of a tertiary referral center in southern Italy

Review

Human papillomavirus self-sampling versus standard clinician-sampling for cervical cancer screening in sub-Saharan Africa: a systematic review and meta-analysis of randomized controlled trials

Review

Emerging role of human polyomaviruses 6 and 7 in human cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits